ERBB2 and breast carcinoma: Von Minckwitz and colleges also demonstrated that pCR was a surrogate end point for patients with triple negative, Luminal B/HER2-, and HER2 positive breast cancer but not for patients with Luminal B/HER2+ disease 34.